FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray LOGIN ABLAdvisor Blue
 
Skip Navigation LinksHome / News / Read News

Print

S&P Global Market Intelligence: Delayed Launches, Slow Sales Drive Drugmakers to Adapt Marketing Amid Pandemic

June 15, 2020, 09:10 AM
Filed Under: Pharmaceuticals

According to an article authored by Michael Gibney, Healthcare Reporter, S&P Global Market Intelligence and published by S&P Global Market Intelligence on June 15, 2020, for some biotech and pharmaceutical companies ready to send new drugs out into the world, the coronavirus pandemic has caused a shift in drug launch practices from face-to-face interactions to virtual communication.

To read the full article from S&P Global Market Intelligence, click here.







Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.

Sector/Economic Data
U.S. Census Bureau – U.S. Department of Commerce
March 2022 Construction Spending Report
U.S. Census Bureau – U.S. Department of Commerce
Full Report on Manufacturers' Shipments, Inventories and Orders - March 2022
view all sector/economic data
Featured Articles
Commercial Finance M&A in 2024: What to Expect After a Slow Year of Deal Flow
Commercial finance M&A was slow in 2023 due to economic uncertainty...
by Tim Stute and Chris Hemler
Full Contact ABL: Collateral Versus Enterprise Value ABL
Charlie Perer contrasts Collateral-focused and Enterprise Value...
by Charlie Perer
Most Popular | All Articles
Sponsored Content
CFG Merchant Solutions Underwriter Academy
CFGMS is proud to announce our new program: Underwriter Academy! Fast-track into a position with one of our producing underwriting teams.
sponsored by:
LEARN MORE